Zeynep Hande Turna|Zeynep Hande Turna, Zeynep Hande Savas Turna, Hande Savaş

Zeynep Hande Turna|Zeynep Hande Turna, Zeynep Hande Savas Turna, Hande Savaş

İstanbul University Cerrahpaşa - İstanbul / Türkiye
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4303252
İstanbul Üniversitesi Cerrahpaşa
person_outline Zeynep Hande Turna|Zeynep Hande Turna, Zeynep Hande Savas Turna, Hande Savaş's MOST POPULAR ARTICLES
1-) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialA Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ...The Lancet 389 (10066), 255-265, 201737912017
2-) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ...The Lancet 393 (10183), 1819-1830, 201919832019
3-) Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non–small-cell lung cancer and programmed death ligand-1 tumor proportion score …G de Castro Jr, I Kudaba, YL Wu, G Lopes, DM Kowalski, HZ Turna, ...Journal of clinical oncology 41 (11), 1986, 2023992023
4-) LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042RS Herbst, G Lopes, DM Kowalski, K Kasahara, YL Wu, G De Castro Jr, ...Annals of oncology 30, xi63-xi64, 20191042019
5-) Extraskeletal Ewing\'s sarcoma family of tumors in adults: prognostic factors and clinical outcomeD Tural, N Molinas Mandel, S Dervisoglu, F Oner Dincbas, S Koca, ...Japanese Journal of Clinical Oncology 42 (5), 420-426, 2012852012